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Abstract 
 
Objective: The objective of the present study was to examine several dimensions of 
quality of life (QoL) and fatigue in patients with adrenal incidentaloma. Research 
methods and procedures:  This was a case-control study designed to analyze patient 
outcomes using three validated generic QoL questionnaires, EQ-5D, SF-36 and MFI-20, 
the results of which were compared to those obtained for age- and sex-matched controls. 
The study population comprised 139 consecutive patients with nonfunctioning adrenal 
masses (104 females, 35 males; age 59.1±10.8) and 139 age- and sex-matched controls. 
Results: Reduced QoL was found in patients with adrenal incidentaloma as compared to 
controls. Dimensions of QoL that were notably affected included mobility (p=0.03), 
performance of usual activities (p=0.002) and anxiety/depression (p=0.04) as evaluated 
using the EQ-5D; physical functioning (p<0.001), physical role (p<0.001), general health 
(p<0.001), vitality (p=0.001), social functioning (p=0.001) and emotional role (p<0.001) 
as evaluated using the SF-36; and physical fatigue (p=0.04) as assessed using the MFI-20 
questionnaire. In addition, perceived health on a visual analogue scale was also 
significantly lower in patients than in controls (64.8±19.2 vs. 77.1±15.1; p<0.001). 
Conclusion: Patients with adrenal incidentaloma reported reduced QoL and a higher level 
of physical fatigue compared to age- and sex-matched controls. This subject will benefit 
from further studies comparing QoL outcomes of laparoscopic adrenalectomy vs. no 
treatment in patients with adrenal incidentaloma.   
 
 
Key words: adrenal incidentaloma, quality of life, subclinical Cushing's syndrome, EQ-
5D, SF-36, MFI-20 
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Introduction 
 
 
Adrenal incidentalomas are clinically inapparent adrenal masses discovered 
incidentally during diagnostic management for other clinical conditions. In the last few 
decades, improvements in imaging techniques and advances in their availability have 
increased the detection of these tumors among the population, making the management of 
these tumors an important aspect of health care. Adrenal tumors are found in 3% of 
persons older than the age of 50, as determined in autopsy studies (1). Another study 
reported that adrenal adenomas were found in up to 10% of patients who died without
 
any 
premortem suspicion of adrenal disease (2). 
Although adrenal incidentalomas are usually benign tumors, several studies have 
demonstrated that they can be associated with poor health outcomes. A study by Terzolo 
et al. (3) showed that subclinical Cushing's syndrome in patients with adrenal 
incidentaloma was associated with an increased risk of metabolic syndrome. Another 
study reported increased cardiovascular risk profiles as well as an increased frequency of 
atherosclerotic plaques in these patients (4). Finally, a few studies have demonstrated 
lower bone mineral densities in patients with adrenal incidentaloma as compared with 
healthy controls (5, 6).  
In view of these data, the effect of adrenal incidentaloma on subjective well-being 
is of great interest. The present study, therefore, examined patient outcomes using three 
generic, validated, quality-of-life (QoL) questionnaires: EuroQol (EQ-5D), Short Form 
36 (SF-36) and Multidimensional Fatigue Index (MFI-20). The patients’ answers were 
compared with those of age- and sex-matched controls.  
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Current recommendation consider adrenalectomy if the adrenal mass is 4 cm or 
greater in diameter, if the mass enlarges significantly during the period of observation, or 
if there is evidence of autonomous hormonal secretion (7). However, with this study we 
propose that the treatment decision should not be based solely on tumor size and hormone 
status but also on patients’ QoL. 
 
 
Materials and Methods 
 
Patients 
The study population comprised 139 consecutive patients in whom adrenal 
masses were discovered incidentally (104 females, 35 males; age: 59.1±10.8 years). 
Patients were recruited in the period between September 2008 and November 2009 from 
the outpatient clinic of the Department of Endocrinology, University Hospital of Zagreb, 
which is the Croatian referral center for adrenal gland disorders. All patients have been 
examined and interviewed by a single endocrinologist (DK). Patients diagnosed with 
pheochromocytoma, aldosteronoma, overt Cushing’s syndrome, adrenal carcinoma and 
adrenal gland metastases were excluded. Before entering the study, each patient signed an 
informed consent form. The Local Ethics Committee approved the study.  
Among the patients examined, 111 (79.9%) had unilateral adrenal masses, 
whereas both glands were affected in 28 (20.1%) patients. Tumors smaller than 4 cm in 
diameter were found in 118 (84.9%) patients, and tumors larger than 4 cm were found in 
21 (15.1%) patients. In 46 (33.1%) patients adrenal incidentaloma was found by 
abdominal ultrasound during routine annual checkup whereas in 93 (66.9%) patients 
indication for CT was nonspecific abdominal pain. However, at the time of examination 
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all patients were free of any symptoms or disease other than hypertension, diabetes and 
dyslipidemia.    
Hypertension, defined as a diastolic blood pressure more than 90 mm Hg or a 
systolic blood pressure more than 140 mm Hg, was present in 95 (68.3%) patients. 
Dyslipidemia, defined as an abnormal plasma lipid status, was present in 60 (56.8) 
patients. Type 2 diabetes mellitus diagnosed using the criteria recommended by the 
American Diabetes Association (8) was present in 18 (12.9%) patients, and 56 (40.3%) 
patients had a body mass index (BMI) above 30 kg/m
2
. Eighteen of 139 patients (12.9%) 
had subclinical Cushing’s syndrome (SCS), defined by the presence of two of the 
following: elevated urinary free cortisol (>379 nmol/24 h), low ACTH level (<2.2 
pmol/l) and plasma cortisol level >82.8 nmol/l following 1 mg overnight dexamethasone 
suppression (9). There were no differences in age, BMI, prevalence of hypertension, 
dyslipidemia or type 2 diabetes between patients with and without SCS. 
For this study, 139 age- and sex-matched control subjects (104 females and 35 
males) were recruited among the friends and neighbors of the study personnel. Patients 
had significantly higher average body mass index (29.2±5.8 vs. 26.4±4.0; p<0.001) and a 
higher prevalence of hypertension (68.3% vs. 46.0%; p=0.002) than controls, while there 
was no difference in the prevalence of dyslipidemia (56.8% vs. 46.0%; p=0,072) type 2 
diabetes (12.9% vs. 14.4%; p=0,727) or other comorbidities. The clinical and 
demographic characteristics of patients with adrenal incidentaloma and controls are 
shown in Table 1. 
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Serum ACTH, serum cortisol and urine cortisol were measured using an 
electrochemiluminescence immunoassay on a Cobas E601 analyzer (Roche Diagnostics 
GmbH, Manheim, Germany).   
   
 
Questionnaires 
 
 Health-related QoL and fatigue were assessed using the EQ-5D, SF-36 and MFI-
20 questionnaires. All patients were asked to fill out the questionnaires during their first 
visit to the endocrinologist. The return rate of questionnaires was 100% (no patient 
refused to participate).  
 The EQ-5D is a well-known, generic QoL instrument that has been used in the 
context of many different diseases. It is a two-part questionnaire comprising five 
questions that cover five dimensions of health: mobility, self-care, pain/discomfort, usual 
activity and anxiety/depression. Three possible answers are offered for each item: no 
problems, some problems or severe problems. The end of the questionnaire includes a 
self-related global valuation of perceived health using a visual analogue scale graded 0 to 
100 (0=worst possible health; 100=perfect health) (10). 
 The SF-36 consists of 36 items assessing eight domains of QoL: physical 
functioning (PF), physical role (RP), bodily pain (BP), general health (GH), vitality (VT), 
social functioning (SF), emotional role (RE) and mental health (MH). Scores range from 
0 to 100, with higher values representing better QoL (11).   
   The MFI-20 is a 20-item self-report instrument designed to measure five different 
dimensions of fatigue: general fatigue, physical fatigue, reduced activity, reduced 
motivation and mental fatigue (12). General fatigue is an overall indicator of fatigue. 
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Physical fatigue indicates the physical sensations related to the feelings of tiredness. 
Reduced motivation and reduced activity concern possible consequences of fatigue, 
namely, a lack of motivation to start an activity and a decreased level of activity. Mental 
fatigue relates to cognitive functions such as ability to focus and concentrate. Each 
dimension of fatigue contains four items that are rated on a five-point Likert scale (range 
between 4 and 20), where higher scores indicate a higher level of fatigue.  
 
Statistics 
 
The normality of the distributions was tested using Shapiro-Wilk W-test, and the 
variance homogeneity was tested using Lindman's test prior to the analysis of correlation 
and between-group differences. Differences between groups with respect to the 
dependent variables were analyzed using the Wilcoxon matched-pairs test. Differences in 
the prevalence of individual conditions were compared using the chi2 test. The 
differences between groups and the impact of categorical variables were estimated by 
MANOVA, and continuous variables were controlled for by using MANCOVA. The 
significance of the correlation between variables and the correlation trend were analyzed 
by Spearman’s rank order correlations test. Statistical significance was defined as p<0.05 
in all analyses, which were carried out using SAS (version 9.1.3.). 
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Results 
 
 Patients with adrenal incidentaloma reported reduced QoL and a higher level of 
physical fatigue compared to age- and sex-matched controls.  
 Figure 1 summarizes the comparison of the EQ-5D domains between patients 
with adrenal incidentaloma and controls. Three of the five dimensions of EQ-5D were 
affected by the presence of an adrenal gland tumor. Significantly more patients than 
controls reported moderate or extreme problems in mobility (40.3% vs. 28.1%; p=0.03), 
usual activity (41.7% vs. 20.9%; p=0.002) and anxiety/depression (60.4% vs. 48.2%; 
p=0.04). There was no significant difference between patients and controls in items 
related to self-care and pain/discomfort. In addition, perceived health on a visual 
analogue scale was significantly lower for patients than for controls (64.8±19.2 vs. 
77.1±15.1; p<0.001).     
 The SF-36 scores in the patients with adrenal incidentaloma and the control group 
is shown in Table 2. Patients reported reduced QoL, as evaluated using the SF-36 
dimensions (p<0.001). The difference was significant for physical functioning (p<0.001), 
physical role (p<0.001), general health (p<0.001), vitality (p=0.001), social functioning 
(p=0.001) and emotional role (p<0.001). The differences remain significant even after 
controlling for BMI and the prevalence of hypertension (physical functioning p=0.008; 
physical role p=0.005; general health p<0.001; social functioning p=0.04; emotional role 
p<0.001) except for the difference in vitality which was of borderline significance 
(p=0.05). 
No difference in MFI-20 dimensions was found between patients and controls, 
except for physical fatigue, which was significantly higher in patients (p=0.04; Table 3). 
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The difference remain significant after controlling for BMI and the prevalence of 
hypertension (p=0.01).  
 In a group of patients with SCS (n=18), QoL scores were not different from those 
reported by other patients with adrenal incidentaloma in any dimension of the EQ-5D, 
SF-36 or MFI-20 questionnaire (all p’s>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10
Discussion  
       
 In the last few decades, the management of adrenal incidentaloma has become an 
important aspect of health care. The treatment decision has been based on hormonal 
status and the size of the tumor rather than on patients' emotional and functional well-
being. Adrenalectomy was considered in patients with functional tumors and in those 
with nonfunctioning adrenal masses larger than 4 cm (7). Although the clinical and 
biochemical characteristics of inapparent adrenal masses have been explored in a number 
of studies (13–16), data related to QoL in these patients are scant. This lack of data seems 
to be an important issue, as it may be argued that the patient's quality of life should also 
be taken into account when considering treatment options. The present study clearly 
demonstrated reduced QoL in the patients with adrenal incidentaloma. Dimensions that 
were notably affected included mobility, performance of usual activities and 
anxiety/depression, as assessed by in EQ-5D; physical functioning, physical role, general 
health, vitality, social functioning and emotional role, as assessed by SF-36, and physical 
fatigue as assessed by the (MFI-20).  
The causal relationship between adrenal incidentaloma and reduced QoL needs to 
be clarified. The psychological aspects of the disease, such as patients’ worries about 
their condition, fear of having a tumor and anxiety about the future, probably impair 
QoL. Furthermore, the fact that even subtle endocrine abnormalities could be associated 
with poor health outcomes is well documented (3–6). Eighteen patients in our study 
group had SCS. Their QoL scores were not found to be significantly different from those 
of other patients with adrenal incidentaloma. However, the use of disease specific 
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CushingQoL questionnaire in the group of patients with SCS would probably be more 
reliable than the use of generic questionnaires (17).  
To our knowledge, this is the first study exploring the QoL in patients with 
adrenal incidentaloma. The most recent study, by Sukor et al., reported impaired QoL in 
patients with unilateral primary aldosteronism that significantly improved by 3 months 
after laparoscopic adrenalectomy (18). Studies on pituitary adenomas, another relevant 
group of endocrine tumors, indicated the impairment of multiple aspects of life quality 
and fatigue in patients as compared to controls (19, 20). Study by Johnson et al. analyzed 
QoL in 51 patients with non-functioning pituitary adenoma prior to treatment and 
demonstrated impairment in both physical and mental measures compared with the 
control population (19). However, some important factors that influence QoL in pituitary 
adenoma are not relevant in adrenal incidentaloma, such us mass effects of the tumor and 
partial or complete hormone deficiency.  
Although our results undoubtedly suggest reduced QoL in patients with adrenal 
incidentaloma, it remains to be determined by further studies whether unilateral 
laparoscopic adrenalectomy can improve QoL in these patients. Studies on pituitary 
tumors demonstrated reduced QoL even after successful removal of the tumor and despite 
optimal hormone substitution (21, 22).  
The present study had several limitations. Three generic questionnaires, EQ-5D, 
SF-36 and MFI-20, were used to analyze different dimensions of QoL and fatigue in 
patients with adrenal incidentaloma. The main advantage of such generic instruments is 
that their scores can be compared with those related to other conditions in different 
populations. However, these questionnaires do not cover more specific aspects of a 
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disease. Therefore, further studies using disease-specific questionnaires are needed to 
confirm our findings. Another shortcoming of the study is the fact that the patients had a 
higher average body mass index and a higher prevalence of hypertension than did the 
control group members, a discrepancy that potentially could have influenced the results. 
However, differences between the patients and controls in a certain domains of SF-36 and 
MFI-20 questionnaires remain significant even after controlling for BMI and the 
prevalence of hypertension. Nevertheless, the fact that the controls did not share the same 
clinical condition that led to the discovery of adrenal incidentalomas in patients could 
bias the results.  Finally, we did not have any information about the socioeconomic status 
of the study participants in either group.   
In conclusion, our study demonstrated impaired QoL in patients with adrenal 
incidentaloma as compared to age- and sex-matched controls. However, since the clinical 
relevance of the results is less obvious, this subject will benefit from further investigation 
that compare the QoL outcomes of laparoscopic adrenalectomy vs. no treatment.   
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Figure 1. Percentage of patients and controls reporting no problems, some problems or 
severe problems in each domain of the EQ-5D. 
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Table 1. Clinical and demographic characteristics of the patients with adrenal 
incidentaloma and controls  
  
 Adrenal 
incidentaloma 
(n=139) 
 
Controls 
(n=139) 
P value 
Age (years) 59.1±10.8 59.1±10.8 NS 
Male/female 35/104  35/104 NS 
BMI (kg/m
2
) 29.2±5.8  26.4±4.0 <0.001 
Hypertension (%) 
 
68.3 46.0 0.002 
Diabetes (%) 12.9 
 
14.4 NS 
Dyslipidemia (%) 
 
56.8  46.0 NS 
 
Results are mean ± SD 
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Table 2. SF-36 scores for the patients with adrenal incidentaloma and for the control 
group. 
 
 Adrenal 
incidentaloma        
(n=139) 
 
 
Controls 
(n=139) 
 
P value 
Physical functioning 62.0±28.3 75.2±28.3 
 
<0.001 
Physical role 55.0±40.8 73.2±37.8 
 
<0.001 
Bodily pain 63.4±24.7 65.9±22.4 
 
NS 
General health 48.6±20.5 58.3±17.6 
 
<0.001 
Vitality 49.5±20.5 55.0±15.0 
 
  0.001 
Social functioning 59.7±25.0 66.5±22.7 
 
  0.001 
Emotional role 52.0±40.5 77.2±35.9 
 
<0.001 
Mental health 58.7±19.7 
 
60.6±14.2 NS 
 
Results are mean ± SD 
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Table 3. MFI-20 scores for the patients with adrenal incidentaloma and for the control 
group. 
 
 Adrenal 
incidentaloma        
(n=139) 
 
 
Controls 
(n=139) 
 
P value 
General fatigue 11.2±1.9 11.4±1.9 
 
NS 
Physical fatigue 12.0±2.1 11.5±1.9 
 
0.04 
Reduced activity 12.2±2.1 12.0±2.2 
 
NS 
Reduced motivation 12.1±2.6 12.3±2.1 
 
NS 
Mental fatigue 10.7±1.9 11.0±2.0 
 
 NS 
 
Results are mean ± SD  
 
 
 
 
